In the last trading session, 65854.0 shares of the Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) were traded, and its beta was 0.52. Most recently the company’s share price was $1.54, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $4.63M. SONN currently trades at a discount to its 52-week high of $18.72, offering almost -1115.58% off that amount. The share price’s 52-week low was $1.41, which indicates that the current value has risen by an impressive 8.44% since then. We note from Sonnet BioTherapeutics Holdings Inc’s average daily trading volume that its 10-day average is 0.31 million shares, with the 3-month average coming to 1.41 million.
Sonnet BioTherapeutics Holdings Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended SONN as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Sonnet BioTherapeutics Holdings Inc is expected to report earnings per share of -11.12 for the current quarter.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) trade information
The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.6000 on recent trading dayincreased the stock’s daily price by 3.75%. The company’s shares are currently up 5.48% year-to-date, but still down -2.53% over the last five days. On the other hand, Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) is -14.92% down in the 30-day period. We can see from the shorts that 40115.0 shares have been sold at a short interest cover period of 0.03 day(s).
Sonnet BioTherapeutics Holdings Inc (SONN) estimates and forecasts
The year-over-year growth rate is expected to be -100.00%, down from the previous year.
Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 85.27%.
SONN Dividends
Sonnet BioTherapeutics Holdings Inc’s next quarterly earnings report is expected to be released in February.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.38% of Sonnet BioTherapeutics Holdings Inc shares, and 0.20% of them are in the hands of institutional investors. The stock currently has a share float of 0.20%.
Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Nov 30, 2024 . The former held 3.0 shares worth $4626.0, making up 0.10% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 1.84 shares worth around $2835.0, which represents about 0.06% of the total shares outstanding.
